The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction

Authors


Carsten Goessl, M.D., Clinical Research Medical Director, Amgen Inc., One Amgen Center Drive, MS 38-2-A, Thousand Oaks, CA 91320. cgoessl@amgen.com

Abstract

Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.

Ancillary